Dissolution profile evaluation of solid pharmaceutical forms containing chloramphenicol marketed in Brazil

Brazilian Archives of Biology and Technology

Volumn 50, Issue 1, 2007, Pages 57-65

  Ferraz, Humberto Gomes ^a   Carpentieri, Leticia Norma ^b   Watanabe, Sayuri Pereira ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF BRASILIA   (Brazil)

Author keywords

Chloramphenicol; Dissolution; Polymorphism

Indexed keywords

EID: 33947246498     PISSN: 15168913     EISSN: 15168913     Source Type: Journal    
DOI: 10.1590/S1516-89132007000100007     Document Type: Article

References (35)

1. Abdou, H.M. (1995), Dissolution. In: GENARO, A.R. Remington: the science and practice of pharmacy. 19.ed. Easton: Mack publishing, v.1. 2077p.
2. Adams, E.; De Maesschalck, R.; De Spiegeller, B.; Heyden, Y.V.; Smeyers-Verbeke, J.; Massart, D.L. (2001), Evaluation of dissolution profiles using principal component analysis. Int. J. Pharm., Amsterdam, v.212, p.41-53.
3. Aguiar, A J.; Krc, Jr, J.; Kinkel, A W.; Samyn, J. (1967), Effect of polymorphism on the absorption of chloramphenicol from cloranphenicol palmitate. J. Pharm. Sci., Washington, v.57, n.7, p. 847-853.
4. Aguiar, A J.; Zelmer, J. E. (1969), Dissolution behavior of polymorphs of chloramphenicol palmitate and mefenamic acid. J. Pharm. Sci., Washington, v.58, n.8, p.983-987.
5. Anderson, C. M. (1966) Australasian J. Pharm., v. 47, S44.
6. apud: HALEBLIAN, J. and McCRONE. W. Pharmaceutical Applications of polymorphism. J. Pharm. Sci., Washington, v. 58, n. 8, p.911-929, 1969.
7. Ansel, H.C.; Popovich, N.G.; Allen JúnIOR, L.V. (2000), Farmacotécnica: formas farmacêuticas and Sistemas de liberação de fármacos. São Paulo: Premier. 568p.
8. Banerjee, S.; Bandyopadhyay, A.; Bhattacharjee, R. C.; Mukherjee, A. K.; Halder, A. K. (1971), Serum levels of chloraphenicol in children, rhesus monkeys, and cats after administration of chloramphenicol plamitate suspension. J. Pharm. Sci., Washington, v.60, n.1, p.153-155.
9. Bolton, S. (1990), Pharmaceutical statistics: practical and clinical applications. 2.ed. New York: Marcel Dekker. 646p. (Drugs and the pharmaceutical sciences, v.44).
10. Borka, L. and Bache-Hansen, K. (1968), Acta Pharm. Suecica, v. 5, p.525.
11. apud: Maeda, T.; Takenaka, H.; Yamahira, Y.; Noguchi, T. Use of rabbits for absorption studies on polymorphs of chloramphenicol plamitate. Chem. Pharm. Bull, Tokyo, v.28, n.2, p.431-436, 1980.
12. Borka, L. (1970), Acta Pharm. Suecica, v.7, p.1.
13. apud: HALEBLIAN, J.K. Characterization of habits and criystalline modification of solids and their pharmaceutical applications. J. Pharm. Sci., Washington, v. 64, n. 8, p. 1269-1288, 1975.
14. Byrn, S.; Pfeiffer, R.; Ganey, M.; Hoiberg, C.; Poochikian, G. (1995), Pharmaceutical solids: a styrategic approach to regulatory considerations. Pharm. Res., New York, v. 12, n.7, p. 945-954.
15. Carstensen, J.T. (2001), Polymorphism. In: Advanced Drug Delivery Reviews. New York: Marcel Dekker, p. 117-131.
16. Dressman, J.B.; Amidon, G.L.; Reppas, C.; Shah, V.P. (1998), Dissolution testing as a prognostic tool for oral drug absorpt: immediate release dosage forms. Pharm. Res., New York, v.15, n.1, p.11-22.
17. Ferraz, H.G. (1997), Avaliação biofarmacêutica in vitro e in vivo (bioequivalência) de comprimidos de ampicilina 500 mg comercializados no Brasil. São Paulo. 135p. Tese de Doutorado - Faculdade de Ciências Farmacêuticas - Universidade de São Paulo.
18. Glasko, A.J., Kinkel, A.W., Alegnani, W.C., Holmes, E.L. (1968), Clinical Pharmacol. Ther., v.9, p.472.
19. apud: SALEH, A.K.; ALI, M.M Some formulation factors affecting disintegration and dissolution of chloramphenicol capsules. Acta Pharm. Suecica, v.9, p.563-572, 1972.
20. Grant, D.J.W. (1999) Theory and origin of polymorphism. In: BRITTAIN, H. G. ed. Polymorphism in Pharmaceutical Solids. New York: Marcel Dekker, p. 1-33.
21. Jozwiakowski, M.J. (2000), Alteration of solid state of the drug substance: polymorphs, solvates, and amorphous forms. In: LIU, R. ed. Water Insoluble Drug Formulation. Boca Raton: Interpharm / CRC Press, p. 525-568.
22. Juhl, R.P. (1973), Factors affecting release us medicaments from hard gelatin capsules. J. Pharm. Sci., Washington, v. 62, n.1, p.170.
23. Kapusnik-Uner, J.E.; Sandre, M.A; Chambers, H.F. Chemotherapy of microbial diseases. In: GOODMAN and GILMAN'S. The Pharmacological Basis of Therapeutics. 9 nd. Edn. New York: Mc Graw-Hill, 1996. p. 831-836.
24. Khan, K.A.; Rhodes, C.T. (1975), The concept of dissolution efficiency. J. Pharm. Pharmacol., Wallingford, v.27, p.48-49.
25. Miyamoto, M. A.; Kiyotaki, T.; Kisoh, N. A.; Mitsunaga, T.; Maeda T. (1973), Differential scanning calorimetry of chloranphenicol palmitate and the phase-transitional behavior of chloraphenicol palmitate observed during preparation of its oral suspension. Chem. and Pharm. Bull., Tokyo, v. 21, n.9, p.1857-1867.
26. Meredith, P.A. (1996), Generic Drugs: Therapeutic equivalence. Drug Safety, v.15, n.4, p.233-XXIV2.
27. Saleh, A.K.; Ali, M.M. (1972), Some formulation factors affecting disintegration and dissolution of chloramphenicol capsules. Acta Pharm. Suecica, v. 9, p.563-572.
28. Shah, V.P.; Noory, A.; Noory, C.; Mccullough, B.; Clarke, S.; Everett, R.; Naviasky, H.; Srinivasan, B.N.; Fortman, D.; Skelly, J.P. (1995), In vitro dissolution of sparingly water-soluble drug dosage forms. Int. J. Pharm., Amsterdam, v.125, p.99-106.
29. Shargel, L.; Yu, A.B.C. (1999), Applied biopharmaceutics and pharmacokinetics, 4ed., New York: McGraw-Hill, p. 129-167.
30. Singhal, D.; Curatolo, W. (2004), Drug polymorphism and dosage form design: a practical perspective. Adv. Drug Del. Rev., Amsterdam, v.56, p.335-347.
31. Skoug, J.W.; Halstead, G.W.; Theirs, D.L.; Freeman, J.E.; Fagam, D.T.; Rohs, B.R. (1996), Strategy for the development and validation of dissolution tests for solid oral dosage forms. Pharm. Technol., Eugene, v.20, n.5, p.58-72.
32. United States Pharmacopeia: USP 27 (2004), Rockville: United States Pharmacopeial Convention.
33. United States. (1997), Department of Healthy and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research. Guidance for Industry. Dissolution testing of immediate release solid oral dosage forms. Rockville: CMC, 1997. 17p. Available at: http://www.fda.gov/cder/guidance/index. htm. Accessed in: 07 Jan 2002.
34. Vieira, S. (1980), Introdução à Bioestatística. 3.ed. Rio de Janeiro: Campus. 196p.
35. Vippagunta, S.R.; Brittain, H.G.; Grant, D.J.W. (2001), Cristalline solids. Adv. Drug. Del. Rev., Amsterdam, v. 48, p. 3-26.